Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding

Biodesix (BDSX) Long-Term Debt Issuances (2019 - 2022)

Biodesix filings provide 4 years of Long-Term Debt Issuances readings, the most recent being $30.0 million for Q4 2022.

On a quarterly basis, Long-Term Debt Issuances changed N/A to $30.0 million in Q4 2022 year-over-year; TTM through Dec 2025 was $30.0 million, a N/A change, with the full-year FY2025 number at $10.0 million, changed N/A from a year prior.
Long-Term Debt Issuances hit $30.0 million in Q4 2022 for Biodesix, up from $15.0 million in the prior quarter.
In the past five years, Long-Term Debt Issuances ranged from a high of $30.0 million in Q1 2021 to a low of -$9.9 million in Q3 2020.
Median Long-Term Debt Issuances over the past 4 years was $6.5 million (2020), compared with a mean of $9.1 million.
The widest YoY moves for Long-Term Debt Issuances: up 19129.49% in 2022, down 99.66% in 2022.
Biodesix's Long-Term Debt Issuances stood at $3.0 million in 2019, then soared by 224.24% to $9.9 million in 2020, then tumbled by 99.21% to $78000.0 in 2021, then soared by 38361.54% to $30.0 million in 2022.
The last three reported values for Long-Term Debt Issuances were $30.0 million (Q4 2022), $15.0 million (Q2 2022), and $103000.0 (Q1 2022) per Business Quant data.